Cargando…
Tackling HCV-3 in Asia: Breakthroughs for Efficient and Cost-effective Treatment Strategies
Hepatitis C virus (HCV) is known to cause chronic hepatitis C, and its sequelae of cirrhosis and hepatocellular carcinoma. Hepatitis C genotype 3 (HCV-3) in particular is notorious for causing accelerated liver fibrosis, cardiovascular, and metabolic effects, thus increasing morbidity and mortality....
Autores principales: | Saeed, Naba, Gurakar, Ahmet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Jaypee Brothers Medical Publishers
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578556/ https://www.ncbi.nlm.nih.gov/pubmed/29201722 http://dx.doi.org/10.5005/jp-journals-10018-1163 |
Ejemplares similares
-
The use of HCV positive donors among non-HCV infected liver transplant recipients
por: Zaffar, Duha, et al.
Publicado: (2022) -
New treatments for HCV: Perspective from Asia
por: Yu, Ming‐Lung, et al.
Publicado: (2015) -
Tackling cardiometabolic risk in the Asia Pacific region
por: Li, Jian-Jun, et al.
Publicado: (2020) -
Keep your eyes on the prize: Tackling breakthrough COVID-19 in MS patients
por: van Kempen, Zoé LE, et al.
Publicado: (2021) -
Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs
por: Paolucci, Stefania, et al.
Publicado: (2017)